Latest Esg Commitments News

Ariana Resources plc is set to raise up to A$15 million through a dual listing on the ASX, aiming to accelerate development at its flagship Dokwe Gold Project in Zimbabwe and repay existing debt. The capital raising also supports ongoing operations and exploration across its diverse portfolio in Türkiye, Kosovo, and Cyprus.

Evolution Energy Minerals has unveiled a strategic update on its development-ready Tanzanian graphite project, announcing a $1.45 million renounceable rights issue to accelerate project development and capitalize on binding offtake agreements.

Canyon Resources has confirmed its Minim Martap Bauxite Project in Cameroon as a world-class, tier-one operation with production set to begin in early 2026. The project boasts over 1 billion tonnes of high-grade bauxite, strong economics, and secured financing.

Tamboran Resources Corporation advances its Beetaloo Basin gas project with record well flow rates and strategic partnerships, targeting initial production by mid-2026. The company is also progressing a farmout for Phase 2 acreage amid rising East Coast gas demand.

Delorean Corporation reported a strategic shift in FY25, transitioning from third-party bioenergy construction to owning and operating renewable gas infrastructure, resulting in a $4.1 million loss but positioning the company for future multi-revenue growth.

Synertec Corporation Limited reported an 8% revenue decline to $18.2 million in FY2025 alongside a $7.64 million net loss, yet its Engineering segment showed a strong EBITDA rebound and its Powerhouse renewable technology revenue nearly doubled.

Elanor Investors Group reported a substantial $157.8 million net loss for FY24 amid asset devaluations and debt covenant breaches, prompting a strategic recapitalisation and leadership transition.

Acrux Ltd reported a 44% revenue decline and a modest increase in net loss for FY25, while expanding its US topical generics portfolio and entering the Saudi Arabian market. The company signals a strategic pivot amid intensifying competition and lower returns.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

NobleOak Life Limited reported robust FY25 results, with a 20% increase in in-force premiums and a 22% rise in underlying NPAT, underpinned by strategic investments in AI and a transition to a capital-efficient Life Company structure.

PEXA Group Limited reported a 16% revenue increase to $393.6 million for FY25, driven by growth across its Australian Exchange, UK International business, and Digital Solutions segments. Despite a statutory net loss of $76.1 million due to impairments and deferred tax derecognition, core EBITDA rose 21% with improved margins.

humm Group Limited reported a remarkable 458% increase in net profit for FY25, driven by strong asset growth and effective cost management. The company also announced a final dividend and highlighted ongoing technology transformation and ESG commitments.